Segment Reporting - Schedule of Significant Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Revenues from External Customers and Long-Lived Assets [Line Items] | ||||||
| Oncology clinical trial related costs | $ 208,021 | $ 30,798 | $ 259,286 | $ 61,671 | ||
| Acquired in-process research and development expense | 0 | 15,007 | 0 | 15,007 | ||
| Stock-based compensation | 478,784 | 11,088 | 489,880 | 20,595 | ||
| Total operating expenses | 568,437 | 59,617 | 635,288 | 102,006 | ||
| Other income, net | 2,729 | 2,334 | 6,667 | 4,371 | ||
| Interest expense | 0 | (3,102) | 0 | (6,223) | ||
| Net loss | (565,708) | $ (62,913) | (60,385) | $ (43,473) | (628,621) | (103,858) |
| Reportable Segment | ||||||
| Revenues from External Customers and Long-Lived Assets [Line Items] | ||||||
| Oncology clinical trial related costs | 67,824 | 19,955 | 104,187 | 41,852 | ||
| Acquired in-process research and development expense | 0 | 15,007 | 0 | 15,007 | ||
| Compensation related costs, excluding stock-based compensation | 16,800 | 10,852 | 32,654 | 19,911 | ||
| Stock-based compensation | 478,784 | 11,088 | 489,880 | 20,595 | ||
| Other expenses | 5,029 | 2,715 | 8,567 | 4,641 | ||
| Total operating expenses | 568,437 | 59,617 | 635,288 | 102,006 | ||
| Other income, net | 2,729 | 2,334 | 6,667 | 4,371 | ||
| Interest expense | 0 | (3,102) | 0 | (6,223) | ||
| Net loss | $ (565,708) | $ (60,385) | $ (628,621) | $ (103,858) | ||
| X | ||||||||||
- Definition Acquired-In-Process Research And Development Expense No definition available.
|
| X | ||||||||||
- Definition Labor And Related Expenses, Excluding Stock-Based Compensation No definition available.
|
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|